SkinMedica invest in cosmeceuticals

- Last updated on GMT

SkinMedica - a specialty pharmaceutical company - is to receive
financing to further expand its cosmeceutical pipeline. The company
has entered a deal with existing, and new investors to sell $25.8
million of its Series D preferred shares.

"This financing exhibits the extremely high caliber of investors that SkinMedica has been able to attract and their belief in the potential for both our pharmaceutical and cosmeceutical product lines. We anticipate that the funding from this round will enable us to expand our pipeline and sustain the growth of our current products,"​ said CEO of SkinMedica Rex Bright.

Funding will be used to expand the pipeline of pharmaceutical and cosmeceutical products and to fund business development activities including possible acquisitions of dermatological products and technologies.

SkinMedica​, which develops and commercialises dermatology products, currently markets a line of cosmeceutical products including TNS Recovery Complex - with antioxidants, matrix proteins and soluble collagens - to reduce the signs of aging.

"SkinMedica's business model is sound and takes advantage of two highly desirable and growing markets in dermatology, pharmaceuticals and cosmeceuticals,"​ said newly appointed MD Andrew Schiff.

US cosmeceutical sales reached $3.4 billion in 2002, according to market research company Freedonia Group, this is only a tiny fraction of the $185.2 billion US pharmaceutical market.

Related topics: Business & Financial, Skin Care

Related news

Show more

Related products

show more

LACTOSPORIN®: A NOVEL COSMECEUTICAL POSTBIOTIC

LACTOSPORIN®: A NOVEL COSMECEUTICAL POSTBIOTIC

SABINSA | 06-Sep-2019 | Data Sheet

Patented technology yields the novel probiotic metabolite, LactoSporin®. Derived from Bacillus coagulans MTCC 5856, but with no live cells, LactoSporin...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars